Document is current
Any future updates will be listed below
-
Authors
Kim, Jonggeol Jeffrey
Bandres-Ciga, Sara
Heilbron, Karl
,
Aslibekyan, Stella
Auton, Adam
Babalola, Elizabeth
Bell, Robert K.
Bielenberg, Jessica
Bowes, Jonathan
Bryc, Katarzyna
Chaudhary, Ninad S.
Coker, Daniella
Das, Sayantan
DelloRusso, Emily
Elson, Sarah L.
Eriksson, Nicholas
Filshtein, Teresa
Fontanillas, Pierre
Freyman, Will
Fuller, Zach
German, Chris
Granka, Julie M.
Hernandez, Alejandro
Hicks, Barry
Hinds, David A.
Jewett, Ethan M.
Jiang, Yunxuan
Kukar, Katelyn
Kwong, Alan
Liang, Yanyu
Lin, Keng-Han
Llamas, Bianca A.
McIntyre, Matthew H.
Micheletti, Steven J.
Moreno, Meghan E.
Nandakumar, Priyanka
Nguyen, Dominique T.
O’Connell, Jared
Petrakovitz, Aaron A.
Poznik, G. David
Reynoso, Alexandra
Saini, Shubham
Schumacher, Morgan
Selcer, Leah
Shastri, Anjali J.
Shelton, Janie F.
Shi, Jingchunzi
Shringarpure, Suyash
Su, Qiaojuan Jane
Tat, Susana A.
Tran, Vinh
Tung, Joyce Y.
Wang, Xin
Wang, Wei
Weldon, Catherine H.
Wilton, Peter
Wong, Corinna D.
Blauwendraat, Cornelis
Noyce, Alastair J. https://orcid.org/0000-0003-3027-5497
-
Funding
Funding for this research was provided by:
Parkinson's UK
Cure Parkinson's Trust
Michael J. Fox Foundation for Parkinson's Research
Innovate UK
NIHR, Alchemab, Virginia Keiley benefaction, Aligning Science Across Parkinson's Global Parkinson’s Genetics Program
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (ZO1 AG000535, ZIA AG000949)
- License Information
-
More Information
Article History
Received: 6 December 2023
Accepted: 11 November 2024
First Online: 5 December 2024
Competing interests
: Members of the 23andMe Research Team are employed by and hold stock or stock options in 23andMe, Inc. K.H. is a former employee of 23andMe Inc., and holds stock and stock options in 23andMe, Inc. A.J.N. reports consultancy and personal fees from AstraZeneca, AbbVie, Profile, Roche, Biogen, UCB, Bial, Charco Neurotech, uMedeor, Alchemab and Britannia outside the submitted work. The remaining authors declare no competing interests.
